BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Regulatory & Policy
FDA schedules July PCAC review for seven peptides as Category 2 compounding restrictions lapse
Twelve peptides — including BPC-157, TB-500, Semax and Epitalon — were removed from the FDA's Category 2 "unsafe to compound" list on 23 April 2026. Seven of them now go before the Pharmacy Compounding Advisory Committee on 23-24 July 2026 for potential addition to the 503A Bulks List. Removal from Category 2 is not the same as authorisation to compound.
05 May 2026
Regulatory & Policy
Peptide industry briefing — March to early May 2026
The single biggest story of 2026 is the RFK-led reclassification moving 14 peptides off the FDA's banned list. Compounded GLP-1s are dying. Mainstream attention is at an all-time high. Counterfeit product remains the trust gap that defines this market.
04 May 2026